Shares of Karyopharm Therapeutics KPTI moved higher by 5.7% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 22.37% year over year to ($0.59), which were in line with the estimate of ($0.59).
Revenue of $35,100,000 rose by 93.97% year over year, which beat the estimate of $29,370,000.
Outlook
Karyopharm Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 11, 2021
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2451/39787
Technicals
Company's 52-week high was at $29.61
Company's 52-week low was at $13.39
Price action over last quarter: Up 17.77%
Company Profile
Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Its pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor, as well as its lead product, include XPOVIO.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
